Millennium Over-Delivers on 2007 Goals and Financia...(tely $450 million (corresponding GAAP R&...)

which includes stock-based compensation expense, are expected to total

approximately $480 million);

-- Non-GAAP net income is expected to be in the range of $80 million to

$95 million;(3)

-- GAAP net income is expected to be in the range of $10 million to

$25 million.(4)

Presentation Reminder

Dr. Dunsire and Ms. Fanucci will present additional detail on 2007 financial results and 2008 goals and financial guidance on February 7, 2008, at the Merrill Lynch 2008 Global Pharmaceutical, Biotechnology & Medical Device Conference. The presentation will be webcast live at 8:00 a.m. ET and may be accessed by visiting the Investors section of the Company's website at: http://www.millennium.com.

About VELCADE

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and J&JPRD. Millennium is responsible for commercialization of VELCADE in the U.S. and Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. For a limited period of time, Millennium and Ortho Biotech Inc. are co-promoting VELCADE in the U.S. VELCADE is approved in 85 countries worldwide. More than 85,000 patients have been treated with VELCADE globally.

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. VELCADE is also indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy. In the European Union and many other countries worldwide, VELCADE is approved for pa
'/>"/>